Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (56898)	12/7/2006 12:47:08 PM
From: hotlinktuna	Read Replies (1) \| Respond to of 59879

Hey Jim just got ANPS .31 -.015 on hard drop from .50 a couple of weeks ago...the stock got upgraded to a 12mo. target of a buck from .50 previously: Research Firm Upgrades Applied NeuroSolutions' Rating, Doubles Price Target Thursday November 30, 8:00 am ET Dutton Associates Cites Collaboration with Eli Lilly and Company VERNON HILLS, Ill.--(BUSINESS WIRE)--Biopharmaceutical company Applied NeuroSolutions, Inc. (OTCBB:APNS - News; www.appliedneurosolutions.com) today announced Dutton Associates, an independent research organization, upgraded its recommendation of the Company's stock to "Strong Speculative Buy" from "Speculative Buy" and raised its 12-month price target to $1.00 a share from $0.50 a share. ADVERTISEMENT In a research note, Dutton Associates noted that Applied NeuroSolutions' agreement with Eli Lilly and Company (NYSE:LLY - News), to develop therapeutics to treat Alzheimer's disease, was the reason behind the upgraded rating and price target increase. The research note is available on the Dutton Associates web site at www.DuttonAssociates.com. About Applied NeuroSolutions: Applied NeuroSolutions, Inc. (OTCBB:APNS - News) is developing novel therapeutic compounds to treat and diagnostics to detect Alzheimer's disease based on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions has discovered biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions has also been working on both a cerebrospinal fluid (CSF) test and a blood test to detect AD at a very early stage. This test can also differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan) according to BioPortfolio, Ltd. For more information, visit www.appliedneurosolutions.com. This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission. Contact: Applied NeuroSolutions Ellen Hoffing, President, CEO 847-573-8000 -------------------------------------------------------------------------------- Source: Applied NeuroSolutions, Inc. Recommended to me by a friend...tuna